{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T07:18:24Z","timestamp":1770016704344,"version":"3.49.0"},"reference-count":39,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2013,12,23]],"date-time":"2013-12-23T00:00:00Z","timestamp":1387756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Bristol-Myers Squibb"},{"name":"Gilead"},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Merck\/Schering Plough"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The treatment of hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) infection with pegylated interferon (<jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>) alfa and ribavirin (800\u00a0mg daily) (<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>) is the standard of care (<jats:styled-content style=\"fixed-case\">SOC<\/jats:styled-content>) for hepatitis C virus genotype 3\u2010infection leading to a sustained virological response (<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>) in around 65% of patients.<\/jats:p><jats:p>A better understanding of the <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> life\u2010cycle has recently resulted in the development of several potential direct\u2010acting antiviral drugs (<jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s) targeting viral proteins (<jats:styled-content style=\"fixed-case\">NS<\/jats:styled-content>3\/4A protease, <jats:styled-content style=\"fixed-case\">NS<\/jats:styled-content>5B nucleos(t)idic and non\u2010nucleos(t)idic polymerase, <jats:styled-content style=\"fixed-case\">NS<\/jats:styled-content>5A viral replication complex). First generation protease inhibitors in combination with <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content> are not efficient in genotype 3\u2010infected patients. The combination of <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content> with Daclatasvir, a <jats:styled-content style=\"fixed-case\">NS<\/jats:styled-content>5A inhibitor for 12\u201324\u00a0weeks results in a <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> in around 75% while the triple combination of <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content> with the oral nucleotidic polymerase inhibitor Sofosbuvir (<jats:styled-content style=\"fixed-case\">GS<\/jats:styled-content>\u20107977) for 12\u00a0weeks in na\u00efve patients results in a <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> in more than 95%. The results of the first oral combination of Sofosbuvir and <jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content> for 12\u00a0weeks in genotype 3\u2010infected patients have been rather disappointing with a slightly lower <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> than after 24\u00a0weeks of <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>: around 60%, and only 30% in patients with cirrhosis. Extending treatment from 12 to 16\u00a0weeks in treatment experienced patients doubled the <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> rate and an 80% <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> rate is expected by extending treatment to 24\u00a0weeks. The best oral combination of new <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s is probably the combination of Sofosbuvir and a <jats:styled-content style=\"fixed-case\">NS<\/jats:styled-content>5A inhibitor (Daclatasvir, Ledipasvir\u2026) for 24\u00a0weeks, which resulted in a 100% <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> rate in a limited series. The use of cyclophilin inhibitors, a host\u2010targeted antiviral, in association with <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s and\/or <jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content> may also be of interest.<\/jats:p><jats:p>The oral combination of new <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s (dual or triple combination of different antivirals) or of <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s and host targets such as cyclophilin will probably become the <jats:styled-content style=\"fixed-case\">SOC<\/jats:styled-content> for genotype 3\u2010infected treatment\u2010na\u00efve or \u2010experienced patients.<\/jats:p>","DOI":"10.1111\/liv.12405","type":"journal-article","created":{"date-parts":[[2013,12,23]],"date-time":"2013-12-23T07:49:39Z","timestamp":1387784979000},"page":"18-23","source":"Crossref","is-referenced-by-count":18,"title":["Treatment of hepatitis C virus genotype 3\u2010infection"],"prefix":"10.1111","volume":"34","author":[{"given":"Stanislas","family":"Pol","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris Descartes APHP Unit\u00e9 d'H\u00e9patologie H\u00f4pital Cochin INSERM U\u20101016 Institut Cochin Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana\u00efs","family":"Vallet\u2010Pichard","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Descartes APHP Unit\u00e9 d'H\u00e9patologie H\u00f4pital Cochin INSERM U\u20101016 Institut Cochin Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Corouge","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Descartes APHP Unit\u00e9 d'H\u00e9patologie H\u00f4pital Cochin INSERM U\u20101016 Institut Cochin Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,12,23]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.070649"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01441.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21850"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.05.016"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"e_1_2_9_9_1","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jhep.2004.02.007","article-title":"Peginterferon alfa\u20102b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3","volume":"40","author":"Zeuzem S","year":"2004","journal-title":"J Hepatol"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.023"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03763.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1645"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02701.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2010.0078"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.9.1345"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21932"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08309"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066403"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24480"},{"issue":"1","key":"e_1_2_9_20_1","first-page":"271A","article-title":"The outcome of 24 vs 48\u00a0weeks of peginterferon alfa\u20102a (40KD) plus ribavirin on sustained virologic response rates in patients infected with genotype 2 or 3 hepatitis C virus who do not achieve a rapid viral response: the N\u2010CORE study","volume":"56","author":"Cheinquer H","year":"2013","journal-title":"Hepatology"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.05.046"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.10.028"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08960"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70138-X"},{"issue":"1","key":"e_1_2_9_25_1","first-page":"S570","article-title":"Daclatasvir combined with peginterferon alfa\u20102a and ribavirin for 12 or 16\u00a0weeks in patients with hepatitis C virus genotype 2 or 3 infection: COMMAND GT 2\/3 study","volume":"58","author":"Dore GJ","year":"2012","journal-title":"J Hepatol"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61217-3"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208953"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70033-1"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104430"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(13)60007-0"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(13)60008-2"},{"key":"e_1_2_9_34_1","unstructured":"LawitzE GhalibR Rodriguez\u2010TorresM et\u00a0al.Suppression of viral load through 4\u00a0week post\u2010treatment results of a once\u2010daily regimen of Simeprevir+Sofosbuvir with or without ribavirin in hepatitis C virus GT 1 null responders. 20thConference on Retroviruses and Opportunistic Infections (CROI 2013). Atlanta March 3\u20106 2013. Abstract 155LB."},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(13)62121\u20102"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(13)61416-6"},{"key":"e_1_2_9_37_1","unstructured":"SulkowskiMS GardinerDF Rodriguez\u2010TorresM et\u00a0al.High rate of sustained virologic response with the all\u2010oral Combination of Daclatasvir (NS5A inhibitor) plus Sofosbuvir (nucleotide NS5B inhibitor) with or without ribavirin in treatment\u2010na\u00efve patients chronically infected with HCV genotype 1 2 or 3. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012). Boston November 9\u201013 2012. Abstract LB\u201002."},{"key":"e_1_2_9_38_1","unstructured":"KowdleyKV LawitzE PoordadF et\u00a0al.A 12\u2010week interferon\u2010free treatment regimen with ABT 450\/r ABT\u2010267 ABT\u2010333 and ribavirin achieves SVR12 rates (observed data) of 99% in treatment na\u00efve patients and 93% in prior null responders in HCV genotype 1 infection. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012). Boston November 9\u201013 2012. Abstract LB\u201001."},{"key":"e_1_2_9_39_1","unstructured":"EversonGT SimsKD Rodriguez\u2010TorresM et\u00a0al.An Interferon\u2010free Ribavirin\u2010free 12\u2010Week Regimen of Daclatasvir (DCV) Asunaprevir (ASV) and BMS\u2010791325 Yielded SVR4 of 94% in Treatment\u2010Naive Patients with Genotype (GT) 1 Chronic Hepatitis C Virus (HCV) Infection. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012). Boston November 9\u201013 2012. Abstract LB\u20103."},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61416-0"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12405","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12405","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.12405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T23:23:45Z","timestamp":1694561025000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.12405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,23]]},"references-count":39,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1111\/liv.12405"],"URL":"https:\/\/doi.org\/10.1111\/liv.12405","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,23]]}}}